RxDoctor Payments Data

Susan Blue, MD

Neurology · Fort Worth, TXNPI 1578540431

Payments from drug & device makers

$15,018in general payments, 2019–2025

Across 310 payments — averaging $48.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$9K
  • Biogen$595
  • Teva Pharmaceuticals USA, Inc.$533
  • AbbVie$497
  • Novartis$431
  • Sanofi$352
  • plus $3K from 35 others

What the payments were for

  • Speaking & faculty fees$7,45650%
  • Travel & lodging$1601%
  • Food & beverage$7,33849%
  • Education$640%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,018 in reported general payments places this provider in the 70th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$59,429
Medicare patients
261
Services billed
453

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Radicava OrsEdaravone13$170,209
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5015$95,873
Glatiramer Acetate11$19,640
AptiomEslicarbazepine Acetate13$15,535
RytaryCarbidopa/Levodopa14$12,094
Pyridostigmine Bromide ErPyridostigmine Bromide21$7,380
Memantine Hcl184$6,575
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone17$4,664
Carbidopa-LevodopaCarbidopa/Levodopa138$4,142
Gabapentin117$3,969
Primidone25$3,881
Levetiracetam87$3,668
Pyridostigmine Bromide30$3,483
Carbamazepine ErCarbamazepine11$3,409
Ropinirole Hcl102$3,256

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$184$15,57744 claims
Upsher-smith Laboratories LLCTopiramate$41$1,60768 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,246 neurology providers in Texas.

Other neurology in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →